NeuroSense Pushes Canada Meeting to May, Eyes Near-Term Alzheimer’s Readout
NeuroSense has moved its Health Canada pre-NDS meeting to May 2026 to include additional clinical, biomarker and survival data for its PrimeC submission. The ALS candidate showed a 65% reduction in death risk and the company expects Alzheimer's clinical and biomarker results in the coming weeks.
1. Health Canada Pre-NDS Meeting Rescheduled
NeuroSense shifted its pre-New Drug Submission meeting with Health Canada from its original date to May 2026. This change is intended to allow the inclusion of newly generated clinical, biomarker and survival data in the briefing package, strengthening the scientific rationale for PrimeC and potentially expediting regulatory review under the NOC/c pathway.
2. Near-Term Alzheimer’s Study Readout
The company anticipates releasing clinical and biomarker readouts from its Alzheimer’s disease program within weeks. These data will inform PrimeC’s multi-mechanistic activity and could serve as an important catalyst ahead of further regulatory interactions and potential filings.
3. ALS Data and Phase 3 Progress
PrimeC’s ALS program previously demonstrated a 65% reduction in risk of death, supported by an expanding biomarker dataset. NeuroSense has secured FDA clearance to initiate the pivotal Phase 3 PARAGON trial in ALS and is positioning these results as key value inflection points through 2026.